Somatic Systems, Inc. (SMAS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.46M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSomatic Systems, Inc. (SMAS) trades at $0.0001. Somatic Systems, Inc. offers a drug-free, non-surgical approach to treating movement disorders, musculoskeletal problems, and pain relief. Market cap: $1.46M, Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SMAS: SMAS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Somatic Systems, Inc. (SMAS) Healthcare & Pipeline Overview
Somatic Systems, Inc. provides non-invasive, drug-free treatments for movement disorders and musculoskeletal pain, differentiating itself through hands-on therapy and exercise programs. Operating within the medical care facilities sector, the company addresses a growing demand for alternative pain management solutions.
What Is the Investment Thesis for SMAS?
Somatic Systems, Inc. presents a unique value proposition within the healthcare sector, offering a drug-free, non-surgical approach to pain management. The company's high gross margin of 90.9% indicates strong pricing power and efficient service delivery. Growth catalysts include expanding its geographic footprint and increasing adoption of alternative pain management therapies. However, the company's negative profit margin of -222.6% raises concerns about its financial sustainability. The company's beta of -127.87 suggests an inverse correlation with the market, potentially offering diversification benefits. Investors should carefully consider the company's profitability challenges and competitive landscape before investing.
Based on FMP financials and quantitative analysis
SMAS Key Highlights
Somatic Systems, Inc. operates in the healthcare sector, providing drug-free and non-surgical pain management solutions.
- The company boasts a high gross margin of 90.9%, indicating efficient service delivery and strong pricing power.
- Somatic Systems, Inc. has a negative profit margin of -222.6%, signaling potential financial sustainability concerns.
- The company's beta of -127.87 suggests an inverse correlation with the market, potentially offering diversification benefits.
- Somatic Systems, Inc. was founded in 1987 and has offices in Massachusetts, Virginia, and New York.
Who Are SMAS's Competitors?
SMAS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MDGEF Medigene AG | $2.59 | 0.00% | $38.2M | — |
| CCM Concord Medical Services Holdings Limited | $3.17 | +7.82% | — | |
| PIII P3 Health Partners Inc. | $6.36 | +1.44% | $20.8M | — |
| DCGO DocGo Inc. | $0.37 | -6.27% | $36.5M | — |
| BTMD biote Corp. | $1.15 | -0.86% | $50.7M | 66 5-pillar |
| MNDR Mobile-health Network Solutions Class A Ordinary Shares | $1.32 | +3.94% | — | |
| JYNT The Joint Corp. | $7.28 | -2.54% | $104M | 70 5-pillar |
| AIRS AirSculpt Technologies, Inc. | $1.77 | +4.12% | $125M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMAS's Key Strengths?
Drug-free and non-surgical approach.
- Experienced therapists and proven techniques.
- High gross margin.
- Addresses a growing demand for alternative pain management.
What Are SMAS's Weaknesses?
Negative profit margin.
- Limited geographic presence.
- Dependence on hands-on therapy, limiting scalability.
- Unknown Disclosure Status
What Are the Key Risks for SMAS?
Negative profit margin raises concerns about financial sustainability.
- Competition from traditional medical practices and physical therapy clinics.
- Changes in healthcare regulations and reimbursement policies.
- Limited geographic presence restricts market reach.
- Dependence on hands-on therapy limits scalability.
What Threats Does SMAS Face?
- Competition from traditional medical practices and physical therapy clinics.
- Changes in healthcare regulations and reimbursement policies.
- Potential for new and more effective pain management therapies.
- Economic downturn affecting patient affordability.
What Are SMAS's Competitive Advantages?
- Proprietary system of natural movement techniques.
- Experienced therapists trained in the Somatic Systems method.
- Strong reputation for providing effective pain relief and improved mobility.
What Does SMAS Do?
Somatic Systems, Inc., founded in 1987 and headquartered in Northampton, Massachusetts, offers a unique approach to treating movement disorders, musculoskeletal problems, and pain relief. Originally named Pivotal Technology, Inc., the company rebranded to Somatic Systems, Inc. to better reflect its core mission. The company's system revolves around natural, non-invasive movement techniques delivered through one-hour hands-on sessions, therapeutic exercise classes, and prescribed home exercises. These methods aim to alleviate pain and limitations stemming from accidents, trauma, and repetitive stress, addressing conditions like back pain, knee pain, joint problems, carpal tunnel syndrome, TMJ, scoliosis, bursitis, sciatica, headaches, and tendonitis. Somatic Systems, Inc. also caters to athletes, offering performance enhancement and injury prevention programs. With additional offices in Virginia Beach, Virginia, and New York, New York, the company extends its reach to serve a broader clientele seeking alternative pain management solutions.
What Products and Services Does SMAS Offer?
- Provides drug-free and non-surgical treatments for movement disorders.
- Offers hands-on therapy sessions using natural movement techniques.
- Conducts therapeutic exercise classes to improve mobility and reduce pain.
- Prescribes home exercises to reinforce therapy and promote long-term recovery.
- Treats conditions such as back pain, knee pain, and carpal tunnel syndrome.
- Offers performance gains and injury prevention programs for athletes.
- Addresses pain and limitations resulting from accidents, trauma, and repetitive stress.
How Does SMAS Make Money?
- Generates revenue through one-hour hands-on therapy sessions.
- Offers therapeutic exercise classes for group sessions.
- Provides customized home exercise programs for individual patients.
What Industry Does SMAS Operate In?
Somatic Systems, Inc. operates within the medical care facilities industry, a segment of the broader healthcare sector. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic pain, and a growing demand for alternative and non-invasive treatments. The competitive landscape includes traditional medical practices, physical therapy clinics, and other alternative medicine providers. Somatic Systems differentiates itself through its specific focus on natural movement techniques and hands-on therapy.
Who Are SMAS's Key Customers?
- Individuals suffering from movement disorders and musculoskeletal problems.
- Patients seeking drug-free and non-surgical pain relief options.
- Athletes looking to improve performance and prevent injuries.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Somatic Systems, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Northampton, US. The company is led by CEO Steven Aronstein. SMAS has traded publicly since 2022.
SMAS Valuation & Market Position
With a $1.46M market cap, Somatic Systems, Inc. sits in the micro-cap segment of the market.
SMAS Financials
SMAS Latest News
-
U.S. job growth smashes expectations in August, unemployment rate remains flat
All News · Sep 4, 2026
-
US economy smashes forecast with 162,000 jobs added in August
International homepage · Sep 4, 2026
SMAS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SMAS.
Price Targets
Wall Street price target analysis for SMAS.
SMAS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SMAS; grades run from A+ (80-100) to F (below 30).
Leadership: Steven Aronstein
CEO
Steven Aronstein serves as the CEO of Somatic Systems, Inc. His background includes extensive experience in healthcare management and a deep understanding of alternative pain management therapies. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise in strategic planning and business development has been instrumental in shaping the company's direction.
Track Record: Under Steven Aronstein's leadership, Somatic Systems, Inc. has expanded its service offerings and strengthened its market position. He has focused on building strategic partnerships and improving operational efficiency. Key achievements include increasing patient volume and enhancing the company's reputation for providing effective pain relief.
SMAS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to comply with the reporting requirements of higher tiers like OTCQX or OTCQB. These companies often have limited operating history, emerging technologies, or face financial challenges. Investing in OTC Other stocks carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to less stringent listing requirements and reduced regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to listed companies.
- Limited regulatory oversight and investor protection.
- Going concern risk due to financial instability.
- Verify the company's registration and legal standing.
- Review available financial statements and assess financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity and trading volume of the stock.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with OTC investing.
- Company has been in business since 1987.
- Physical office locations in multiple states.
- Offers a specific and defined service.
- CEO is identified.
Common Questions About SMAS (Healthcare)
What do analysts say about SMAS stock?
As of 2026-03-17, there is no available analyst coverage for Somatic Systems, Inc. (SMAS). Given its OTC Other listing and limited financial disclosure, formal analyst ratings and price targets are unlikely.
What are the main risks for SMAS?
The main risks for Somatic Systems, Inc. include its negative profit margin, which raises concerns about its long-term financial sustainability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited, impacting the depth of analysis.
- OTC status introduces higher risk and uncertainty.